<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333137</url>
  </required_header>
  <id_info>
    <org_study_id>P276-00/52/10</org_study_id>
    <nct_id>NCT01333137</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin</brief_title>
  <official_title>An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piramal Enterprises Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Piramal Enterprises Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      P276-00 is a novel, potent, small-molecule, flavone-derived Cdk 4 D1, Cdk1 B, and Cdk9 T&#xD;
      inhibitor, with potent cytotoxic effects against chemosensitive and chemoresistant cancer&#xD;
      cell lines.This study is planned to compare efficacy of the standard chemotherapy regimen of&#xD;
      gemcitabine and carboplatin when administered with or without P276-00 in subjects with&#xD;
      advanced triple negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression free survival</measure>
    <time_frame>1 year and above</time_frame>
    <description>The primary efficacy endpoint will be median progression-free survival (PFS), defined as the time from the beginning of study treatment to the occurrence of documented disease progression or recurrence, or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 6 months</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival at 6 months</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>upto 3 years and above</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>upto 3 years and above</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000 mg/m2/day on Days 1 &amp; 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P276-00 along with Gemcitabine and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 &amp; 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Carboplatin</intervention_name>
    <description>Gemcitabine 1000 mg/m2/day on Days 1 &amp; 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.</description>
    <arm_group_label>Gemcitabine and Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P276-00 along with Gemcitabine and carboplatin</intervention_name>
    <description>In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 &amp; 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.</description>
    <arm_group_label>P276-00 along with Gemcitabine and carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females of age ≥18 years.&#xD;
&#xD;
          2. Histologically documented metastatic triple negative breast cancer (any triple&#xD;
             negative breast cancer for Phase I)&#xD;
&#xD;
          3. Two or fewer chemotherapy regimens for advanced disease (no limit of prior regimens&#xD;
             for Phase I)&#xD;
&#xD;
          4. ECOG performance score of 1 or less&#xD;
&#xD;
          5. Presence of measurable disease by RECIST 1.1 criteria (not for the Phase I portion)&#xD;
&#xD;
          6. Ability to understand and the willingness to sign a written informed consent document&#xD;
             (ICD)&#xD;
&#xD;
          7. Full recovery from all prior treatment toxicities to Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE V.4) Grade ≤ 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy or biologic/targeted anticancer agents within 4 weeks of study drug&#xD;
             administration&#xD;
&#xD;
          2. Prior radiation therapy within 6 weeks of study drug administration&#xD;
&#xD;
          3. Subject with known active CNS metastases and/or carcinomatous meningitis. However,&#xD;
             subjects with CNS metastases who have completed a course of therapy would be eligible&#xD;
             for the study provided they are clinically stable for at least 1 month prior to entry&#xD;
             as defined as: (1) no evidence of new or enlarging CNS metastasis or new neurological&#xD;
             symptoms attributable to CNS metastases (2) off steroids that are used to minimize&#xD;
             surrounding brain edema.&#xD;
&#xD;
          4. Prior therapy with gemcitabine or a platinum agent (not for the Phase I part)&#xD;
&#xD;
          5. Prior therapy with a Cdk/cyclin inhibitor or any flavones derivative&#xD;
&#xD;
          6. QTc interval &gt;450 msec (using Fridericia's formula)&#xD;
&#xD;
          7. Any acute illness including uncontrolled diabetes, symptomatic or otherwise&#xD;
             uncontrolled cardiac disease (coronary artery disease, arrhythmias, congestive heart&#xD;
             failure) or other illness that in the judgment of the investigator would introduce&#xD;
             additional medical risks&#xD;
&#xD;
          8. Visceral crisis including extensive liver disease with&gt;50% parenchymal involvement or&#xD;
             lymphangitic pulmonary disease&#xD;
&#xD;
          9. History of other prior malignancies except for properly treated basal cell or squamous&#xD;
             cell carcinoma of skin, in situ cervical cancer, or in situ breast cancer&#xD;
&#xD;
         10. Expected survival of less than 3 months&#xD;
&#xD;
         11. Hemoglobin &lt;9.0 gm/dL&#xD;
&#xD;
         12. Absolute neutrophil count &lt;1500/mm3&#xD;
&#xD;
         13. Platelet count &lt;100,000/mm3&#xD;
&#xD;
         14. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt;3 × institutional&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
         15. Total bilirubin, &gt;1.5 × institutional ULN&#xD;
&#xD;
         16. Serum creatinine &gt;1.5 mg/dL&#xD;
&#xD;
         17. Subjects with known infection with human immunodeficiency virus (HIV), tuberculosis,&#xD;
             Hepatitis C or Hepatitis B&#xD;
&#xD;
         18. Pregnant or lactating women&#xD;
&#xD;
         19. Women of childbearing potential not willing to use approved methods of contraception&#xD;
             after signing the ICD, during the entire study and for at least 4 weeks after&#xD;
             completion of study or following withdrawal from the study&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Debasish Tripathy</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC/Norris Comprehensive Cancer Center 1441 Eastlake Avenue, Rm 3440, Los Angeles, CA 90033</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Disney Cancer Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3855 Health Sciences Drive</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>April 8, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

